Brogan T V, Bratton S L, Meyer R J, O'Rourke P P, Jardine D S
Department of Pediatrics, Children's Hospital and Regional Medical Center and University of Washington School of Medicine, Seattle, USA.
J Crit Care. 2000 Mar;15(1):5-11. doi: 10.1053/jcrc.2000.0150005.
The purpose of this study was to quantitate the contribution of nonpulmonary organ failure to mortality of patients treated with high-frequency oscillatory ventilation (HFOV) and to determine which gas-exchange differences are associated with improvement on HFOV.
Charts of all patients treated with HFOV in our pediatric intensive care unit from January 1992 until January 1997 were retrospectively reviewed.
Sixty-six patients were treated and 21 patients improved during HFOV (group 1); 45 patients did not improve (group 2). Seventeen patients (26%) had isolated respiratory failure and their mortality was 12%. Percentages of patients with 2, and 3 or more organ failure were 45%, 29%, and their mortality was significantly higher, 67% and 95%, respectively. Patients with primary respiratory failure demonstrated a significantly greater risk of improvement on HFOV (RR ratio of 2.5, 95% CI 1.5 to 4.2). There was a significantly greater proportion of patients with primary cardiac failure who did not improve on HFOV compared with all other patients. Oxygenation index significantly improved over the first 72 hours for both groups, but then significantly worsened over the next 48 hours in group 2 but not in group 1.
Patients with nonpulmonary organ failure were significantly less likely to improve on HFOV and had a significantly higher mortality than patients with isolated respiratory failure. Children who do not improve on HFOV appear to reach a plateau in oxygenation indices after 3 days of HFOV.
本研究旨在定量分析非肺部器官衰竭对接受高频振荡通气(HFOV)治疗患者死亡率的影响,并确定哪些气体交换差异与HFOV治疗效果的改善相关。
回顾性分析了1992年1月至1997年1月在我院儿科重症监护病房接受HFOV治疗的所有患者的病历。
66例患者接受了治疗,其中21例患者在HFOV治疗期间病情改善(第1组);45例患者病情未改善(第2组)。17例患者(26%)仅有呼吸衰竭,其死亡率为12%。伴有2个及3个或更多器官衰竭的患者比例分别为45%、29%,其死亡率显著更高,分别为67%和95%。原发性呼吸衰竭患者在HFOV治疗后病情改善的风险显著更高(相对危险度比值为2.5,95%可信区间为1.5至4.2)。与所有其他患者相比,原发性心力衰竭患者在HFOV治疗后病情未改善的比例显著更高。两组患者的氧合指数在最初72小时内均显著改善,但在接下来的48小时内,第2组显著恶化,而第1组未出现这种情况。
与仅有呼吸衰竭的患者相比,非肺部器官衰竭患者在HFOV治疗后病情改善的可能性显著降低,死亡率显著更高。在HFOV治疗3天后,病情未改善的儿童的氧合指数似乎达到平台期。